JPH02250832A - Immunological enhancing agent for fishes and feed for fish-farming - Google Patents
Immunological enhancing agent for fishes and feed for fish-farmingInfo
- Publication number
- JPH02250832A JPH02250832A JP1073152A JP7315289A JPH02250832A JP H02250832 A JPH02250832 A JP H02250832A JP 1073152 A JP1073152 A JP 1073152A JP 7315289 A JP7315289 A JP 7315289A JP H02250832 A JPH02250832 A JP H02250832A
- Authority
- JP
- Japan
- Prior art keywords
- fish
- glycyrrhizin
- feed
- fishes
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 42
- 235000019688 fish Nutrition 0.000 title abstract description 40
- 230000002708 enhancing effect Effects 0.000 title abstract description 7
- 238000009372 pisciculture Methods 0.000 title abstract description 4
- 230000001900 immune effect Effects 0.000 title abstract 5
- 239000004378 Glycyrrhizin Substances 0.000 claims abstract description 46
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 46
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 46
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 46
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 46
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000003623 enhancer Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 230000003908 liver function Effects 0.000 abstract description 10
- 230000037396 body weight Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 150000003648 triterpenes Chemical class 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 238000009395 breeding Methods 0.000 abstract 1
- 230000001488 breeding effect Effects 0.000 abstract 1
- 238000009313 farming Methods 0.000 abstract 1
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000238366 Cephalopoda Species 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000019512 sardine Nutrition 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000001937 non-anti-biotic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241001310494 Ammodytes marinus Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010063743 Hypophagia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000237503 Pectinidae Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000500840 Spondyliosoma cantharus Species 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000001639 hypophagic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020637 scallop Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
[B業上の利用分野]
本発明は、魚類の肝機能を強化してその免疫力を高める
ための剤及び本則を含む養魚用餌料に関する。
[従来の技術]
(1)背景
今日、各地の河川、湖沼、海湾などの内水面においては
、コイ、ニジマス、ウナギ、アユ、ボラ、ブリ、クロダ
イ、クルマエビ、マダイ、イカ、タコ、アワビ、カキ、
ホタテガイなどの養殖が盛んに行われており、3万km
にも及ぶ長大な海岸線を持つ我が国では、遠洋漁業にお
ける制約とも相まって、養殖乃至栽培漁業が益々重要性
を加えつつある。
(2従来技術の問題点
しかし、狭い水圏内に多数の魚介を飼養するこれら集約
漁業では、食べ刺し餌料や排泄物の腐敗などのため、生
活環境が自然状態に比べて劣悪な状態となるのが常であ
り、このため伝染性の病気が蔓延しやすい、そこで、餌
料中に抗生物質などの薬剤を添加することが普通に行わ
れているが、薬剤の投与は耐性菌の出現を促進するのみ
でなく、当該薬剤が魚介類の体内に蓄積され、結局最終
捕食者であるヒトが摂取することになるから、公衆衛生
的にも好ましくない(現に、抗生物質の残存量は厳しく
規制されている。)。
従って、若し可能ならば、魚介類自体の免疫力を高める
ことによって疾病に罹患しにくくすることにより、薬剤
の飼養を不必要とすることが望まれる。
[発明が解決しようとする課題]
本発明は、上の課題に応え、魚類の生体防御機能を高め
るための非抗生物質系稟剤及び当該薬剤を含有する餌料
を開発することによって、上記問題を解決するための手
段を提供するのを目的とする。[Field of Industrial Application B] The present invention relates to a fish feed containing an agent and principles for strengthening the liver function of fish and increasing their immunity. [Prior art] (1) Background Today, carp, rainbow trout, eel, sweetfish, mullet, yellowtail, black sea bream, prawn, red sea bream, squid, octopus, abalone, and oysters are found in the inland waters of rivers, lakes, seas, and bays. ,
Cultivation of scallops and other species is actively carried out, and the area is 30,000 km long.
In Japan, which has a long coastline extending over 1,000 yen, aquaculture and cultivated fishing are becoming increasingly important due to restrictions on deep-sea fishing. (2) Problems with the conventional technology However, in these intensive fisheries where large numbers of fish and shellfish are kept in a small aquatic area, the living environment becomes worse than the natural state due to rotting bait and excrement. Therefore, it is common practice to add drugs such as antibiotics to the feed, but the administration of drugs promotes the emergence of resistant bacteria. Not only that, but the drugs accumulate in the bodies of fish and shellfish, and end up being ingested by humans, who are the ultimate predators, which is unfavorable from a public health standpoint (in fact, the amount of antibiotics remaining is strictly regulated). Therefore, if possible, it is desirable to make the feeding of drugs unnecessary by increasing the immunity of fish and shellfish themselves, thereby making them less susceptible to diseases. In response to the above-mentioned problems, the present invention provides means for solving the above-mentioned problems by developing a non-antibiotic drug for increasing the biological defense function of fish and a feed containing the drug. The purpose is to provide.
[課題を解決するための手段〕
(1)概念
本発明者は、上記課題を解決するため鋭意検討を加えた
過程で、グリチルリチンの持つ哺乳動物に対する肝機能
及び免疫増強作用に着目し、魚類への薬理作用を観察し
たところ、下等な魚類においても哺乳動物の場合と類似
の作用が観察されたのみでなく、実際に連鎖球菌に対す
る免疫試験においても、有意の差異が認められた0本発
明は、この知見を基礎とするものである。
(21概要
本発明の要旨は、グリチルリチンを魚類の免疫増強剤と
して利用すること及びそのための簡便な手段として、グ
リチルリチンを養魚用の餌料中に含有させる点に存する
。
以下、発明を構成する諸要素等につき項分けして説明す
る。
(3) グリチルリチン
グリチルリチン(glycyrrhizin) (下
式)は、南ヨーロッパから中央アジアにかけて自生する
マメ科植物カンゾウ(甘草) CGIycyrrhjz
a 1labraL、 、 G、11abra L、v
ar、11anduljfera Re1.et He
rd。
G、echinata L、、 G、 uralens
fs fi#sch et DC,等)の根に含まれる
トリテルペン系配糖体であって、そのアグリコンはグル
クロン酸ダイマーである。
G4+ グリチルリチンの魚類に対する作用(a)測
定項目
(イ)肝機能及び免疫増強機能:グリチルリチン投与開
始から3週間後に、各群から5尾づつ取り上げ、増重率
、ヘマトクリット値(赤血球容積率)、血清蛋白量、血
清アルブミン量、GOT (グルタミン酸−オキサロ酢
酸トランスアミナーゼ)値、GPT(グルタミン酸−ビ
ルピン酸トランスアミナーゼ)値、補体価、リゾチーム
活性、副腎マクロファージ貧食活性及びTNP−BSA
に対する凝集抗体価を測定した。
(T?)感染防御能:グリチルリチン投与開始から4週
間後に、連鎖球菌S−2433株の生菌で攻撃し、感染
防御機能の変化を観察した。
(b)実験方法
(イ)供試魚:高知県土佐市宇佐町の養殖業者より購入
した平均体重15.8gのブリ稚魚を用いた。
(υ)飼育方法:供試魚を帆8LのFRP製水槽に収容
し、エアレーションを行いながら飼育した。
(八)供試グリチルリチン:純度98%以上の高純度品
。
に)グリチルリチンの投与法:魚体重の12%量のイカ
ナゴミンチにグリチルリチンを、魚体重IKg当たり夫
々0(対照) 、2.5.5.0゜25.0及び50.
0II1gを展着剤((スタッシュ)大日本製薬■製)
と共に、−日一回、35日日間(5週間)投与した。
(ホ)免疫方法:グリチルリチン投与前に、TNP化牛
血清アルブミン(TNP−BSA)を供試魚の腹腔内に
接種した。対照区には整理食塩水を同様に接種した。
(へ)血液及び血漿の採取:第二回目の抗原接種から3
週間口に、各区10尾の魚を取り上げ、ヘパリン処理し
たシリンジを用いて心臓穿刺法により血液を採取した。
この血液を一夜4℃で保存後、遠心分離して血漿を採取
した。
(ト)血漿成分の測定:ヘマトクリット値の測定は常法
により行った。血清蛋白量は、ビユレット法により測定
した。血清中のGOT及びGPT値の測定は、夫々<G
OT UVテストワコー)及び<GPT UVテストワ
コー)(共に和光純薬■製)を用いて実施した。
(チ)血清補体価の測定:ウサギ赤血球を用い、Sa
fat iら(1982)の方法により測定した。
(す)副腎細胞の貧食活性の測定:採血した供試魚から
直ちに副腎を取り出し、0.15%の食塩を含むL −
Is (Flow Laboratory)培地中で鋏
を用いて細切した後、白金メツシュで濾過して1×10
7細胞/−濃度の白血球浮遊液を作成した。賞食用粒子
には、各抗原を感作したラテックス(0,81μi、D
ifco)とFXCを用いた。感作ラテツクスの作製は
、高木・補出(19g2 >の方法により行った。貧食
は、細胞浮遊液0.5−と自己血清0.4m、 lX
l0’細胞/−に調整した貧食粒子0.1−を混合し、
25℃で3時間反応させた。
反応後、混合液100μgを取り出し、400×gの角
速度で5分間遠心して得られた沈渣を10−のウシ胎児
血清に懸濁してスメアを作製した。このスメアを乾燥後
、10%ホルマリン加エタノールで固定し、ペルオキシ
ダーゼ染色及びギムザ染色を行った後、検鏡し、100
個の貧食細胞に取り込まれた粒子数を算出した。
(ヌ)凝集抗体価の測定: THP−BS^を感作させ
たヒツジ赤血球(SRBC)を抗原として、マイクロタ
イター法により測定した。抗原の感作は、グルタルアル
デヒド処理5R8Cを用い、常法に従って行った。
(ル)実験的感染試験:グリチルリチン投与4週間後に
、供試魚を連鎖球菌に対する感染試験を行った。
先ず、BH1平板にて30℃、24時間培養した5tr
eptococcus sp、2433株の生菌体を滅
菌リン酸塩緩衝液に5.2 X 10’ CFU/−と
なるように懸濁し、この懸濁液各0.1−を、各区10
尾の供試魚の腹腔内に接種しな。
この実験的感染10日間飼育を続け、生残率の変化を調
べた。なお、各斃死魚は、夫々の腎臓から菌分離を行い
、抗5treptococcus血清を用いて連鎖球菌
症による斃死であることを確認した。
(c)実験結果
(イ)体重変化:グリチルリチン投与量と非投与区の体
重変化は添付第1図に示される。
図示の如く、グリチルリチン投与量が増加する程、実験
開始時−実験終了時曲線間の開きが大きくなる傾向が窺
われ、グリチルリチンの投与が稚魚の体重増加に有効で
あることが知られる。この原因は不明であるが、略々下
記のいづれかと考えてよいであろう。
■ 餌の質をグリチルリチンが改善した。
■ 免疫増強作用(補体価の上昇)との共同作用による
体質改善。
■ グリチルリチンによるの解毒作用の効果。
■ グリチルリチンによる肝機能向上の効果。
(ロ)血液性状の変化:グリチルリチンの投与によるヘ
マトクリット値及び血清蛋白量の変化は第2図に示され
る。
図示の通り、ヘマトクリット値及び血清蛋白量は、いづ
れもグリチルリチンの投与によって増加しており、投与
が血液の性状を良化していることが判る。因に、イワシ
ミンチのような酸化油脂含量の高い餌料を与えた場合、
ヘマトクリット値が低下することが知られているが、グ
リチルリチンを投与するとこの欠点が改善又は解消され
る。
(約肝機能の向上:グリチルリチンの投与が血清中のG
OT及びGPTの値に及ぼす影響は第3図に示される。
図示のように、グリチルリチンの投与によって、かつ投
与量に比例してGOT及びGPTの値が低下しており、
グリチルリチンによる肝機能向上の事実を窺うことがで
きる。
−iにハマチ養殖用の餌料は酸化油脂及び細菌の量が多
いため質が悪く、被養魚の肝機能を低下させ易い、この
ため連鎖球菌症などに感染する場合が多いが、グリチル
リチンは、肝機能強化を通じてこの問題を克服できる可
能性を示す、なお、本実験時の餌料は、前記の如くイカ
ナゴミンチが主体であるが、実際に利用されるイワシミ
ンチでは、より大きな差異が現れるであろう。
(ニ)免疫増強作用:第4図は、グリチルリチンの投与
が免疫力に関連する指標である補体価、リゾチーム活性
、貧食率及び凝集抗体価に及ぼす影響を示す。特に、グ
リチルリチン多量投与群におけるマクロファージ貧食率
の上昇は著しい、これらの結果から、グリチルリチンは
、既に)−11V(エイズウィルスなど)に対して認め
られているのと同様、魚類の病原菌に対しても免疫力を
強化する作用を奏する事実が推測される。このため、被
投与魚体の病原細菌やウィルスに対する抵抗力が増大し
、魚体を良好な健康状態に保つ効果を奏すべきことが期
待される。
〈ホ)連鎖球菌症に対する感染防御効果:第5図は、グ
リチルリチンの投与開始から4週間後に、連鎖球菌S−
2433株のL Om。量を接種したときのグリチルリ
チン投与量と生存率との関係を示す、このグラフから、
グリチルリチンは抗生物貫程劇的な作用を呈しないもの
の、投与量50mg/にg以上のレベルでは、生存率増
加のため原著な効果を奏することが明瞭である。
因に、実際の養魚場では、たとえ病気が発生してもL
D m。程のレベルとは側底ならないので、この程度の
緩和な効果であっても実用的に充分である。
(51投与量及び餌料組成
本発明に係る魚類の肝機能剤及び強化及び養魚用餌料は
、対象魚類に対し、体重IKg当たり5mg以上、好ま
しくは1011g以上投与される。所望によりナトリウ
ム塩若しくはカリウム塩のような易溶性の塩又はカルシ
ウム塩若しくはアルミニウム塩のような難溶性の塩の形
で適用されてもよい。
相手が魚類である関係で、投与は餌料中に混ぜて行うの
が普通である。餌料としては、魚類の種類に応じ、魚粉
、サナギ粉、生魚肉のミンチ、穀粉、麩などが利用され
るが、いずれにしても、公知の粘結剤、例えばα化澱粉
、コムギブルチン、カゼインナトリウム、アルギン酸ナ
トリウム、ポリアクリル酸ナトリウム、カルボキシメチ
ルセルロースナトリウム、各種植物ガム、ダイズホエイ
等を用いて水中で容易には崩壊しない程度の粘結性を与
えておく必要がある。
[作用]
発明者の研究により、グリチルリチンは、魚類に対して
も肝機能向上、解毒、免疫増強等の作用を有することが
発見された。従って、これを魚類の養殖に利用すれば、
POVの高い劣悪な餌料にも悪影響を受けず、かつ高密
度の養殖でも疾病に冒され難い良好な飼育成績を奏する
。しかもグリチルリチンは天然物であって、抗生物質の
ように自然界の微生物バランスを崩したり又は魚体中に
蓄積したりすることがないから、安全な餌料添加物とし
て好適に利用されることが出来る。
[実施例]
以下、実施例により発明実施の態様を説明するが、例示
は単に説明用のもので、発明思想の制限又は限定を意味
するものではない。
生イワシ1kgに、α化澱粉50g、グリチルリチン2
0mg及びビタミンE(酸化防止剤> 10mgをミン
チでにかけて播潰物をラドン状に押し出し、熱風で軽く
乾燥させてブリ稚魚用生餌料約1kgを得た。
【発明の効果]
以上説明しかつ実証した通り、本発明は、魚類の生体防
御機能を高めるための非抗生物質薬剤及び当該薬剤を含
有する餌料を開発することによって、上記問題を解決す
るための手段を提供しえたことにより、栽培漁業の発展
に寄与しうる。
(以下余白)[Means for Solving the Problems] (1) Concept In the process of conducting intensive studies to solve the above problems, the present inventor focused on the liver function and immune-enhancing effects of glycyrrhizin on mammals, and applied it to fish. When we observed the pharmacological effects of the present invention, not only were effects similar to those observed in mammals observed in lower fish species, but also significant differences were observed in an immunity test against streptococci. is based on this knowledge. (21 Overview The gist of the present invention is to utilize glycyrrhizin as an immune enhancer for fish, and to include glycyrrhizin in feed for fish farming as a simple means for that purpose. Below, various elements constituting the invention will be described. (3) Glycyrrhizin Glycyrrhizin (formula below) is a legume that grows wild from southern Europe to central Asia.
a 1labra L, , G, 11abra L, v
ar, 11anduljfera Re1. et He
rd. G, echinata L,, G, uralens
It is a triterpene-based glycoside contained in the roots of fs fi#sch et DC, etc.), and its aglycone is a glucuronic acid dimer. G4+ Effect of glycyrrhizin on fish (a) Measurement items (a) Liver function and immune enhancement function: Three weeks after the start of glycyrrhizin administration, 5 fish were taken from each group and weight gain rate, hematocrit value (red blood cell volume percentage), serum Protein content, serum albumin content, GOT (glutamate-oxaloacetate transaminase) value, GPT (glutamate-virupate transaminase) value, complement value, lysozyme activity, adrenal macrophage phagocytic activity, and TNP-BSA
The agglutinated antibody titer was measured. (T?) Infection protection ability: Four weeks after the start of glycyrrhizin administration, the cells were challenged with live Streptococcus S-2433 strain and changes in infection protection ability were observed. (b) Experimental method (a) Test fish: Young yellowtail fish with an average weight of 15.8 g purchased from a fish farmer in Usa-cho, Tosa City, Kochi Prefecture were used. (υ) Rearing method: Test fish were housed in an FRP aquarium with an 8L sail and reared while being aerated. (8) Test glycyrrhizin: High purity product with purity of 98% or more. 2) Glycyrrhizin administration method: Glycyrrhizin was added to minced squid in an amount of 12% of the fish body weight at doses of 0 (control), 2.5, 5.0, 25.0 and 50.
0II1g as a spreading agent ((Stash) manufactured by Dainippon Pharmaceutical ■)
The drug was also administered once on -day for 35 days (5 weeks). (e) Immunization method: Before administration of glycyrrhizin, TNP-modified bovine serum albumin (TNP-BSA) was intraperitoneally inoculated into the test fish. Control plots were similarly inoculated with saline. (f) Collection of blood and plasma: 3 from the second antigen vaccination
Every week, 10 fish from each group were taken, and blood was collected by cardiac puncture using a heparin-treated syringe. This blood was stored overnight at 4°C and then centrifuged to collect plasma. (g) Measurement of plasma components: Hematocrit values were measured by a conventional method. Serum protein level was measured by the Biulet method. Measurement of GOT and GPT values in serum was performed at <G
The test was carried out using OT UV Test Wako) and <GPT UV Test Wako) (both manufactured by Wako Pure Chemical Industries, Ltd.). (H) Measurement of serum complement value: Using rabbit red blood cells, Sa
It was measured by the method of Fati et al. (1982). (S) Measurement of hypophagic activity of adrenal cells: Immediately remove the adrenal glands from the blood sampled fish, and remove
After cutting into small pieces using scissors in Is (Flow Laboratory) medium, filtering through a platinum mesh to 1×10
A leukocyte suspension with a concentration of 7 cells/- was prepared. The prize edible particles were latex sensitized with each antigen (0.81μi, D
ifco) and FXC were used. The sensitized latex was prepared by the method of Takagi and Hideshi (19g2).
Mix 0.1 − of phagocytic particles adjusted to 10′ cells/−,
The reaction was carried out at 25°C for 3 hours. After the reaction, 100 μg of the mixture was taken out and centrifuged at an angular velocity of 400×g for 5 minutes, and the resulting precipitate was suspended in 10-fetal bovine serum to prepare a smear. After drying, this smear was fixed with 10% formalin and ethanol, peroxidase staining and Giemsa staining, and microscopic examination.
The number of particles taken up by each phagocyte was calculated. (J) Measurement of agglutination antibody titer: Measurement was carried out by a microtiter method using sheep red blood cells (SRBC) sensitized with THP-BS^ as an antigen. Antigen sensitization was performed using glutaraldehyde-treated 5R8C according to a conventional method. (l) Experimental infection test: Four weeks after administration of glycyrrhizin, the test fish were tested for infection with streptococci. First, 5tr was cultured on a BH1 plate at 30°C for 24 hours.
Eptococcus sp., strain 2433, was suspended in sterile phosphate buffer at a concentration of 5.2 x 10' CFU/-, and 0.1- of this suspension was added to 10 cells in each section.
Inoculate the tail of the test fish intraperitoneally. This experimental infection was continued for 10 days and changes in survival rate were examined. In addition, bacteria were isolated from each kidney of each dead fish, and using anti-5 treptococcus serum, it was confirmed that the fish had died due to streptococcus disease. (c) Experimental results (a) Body weight change: The weight change in the glycyrrhizin administration group and the non-administration group are shown in the attached Figure 1. As shown in the figure, it can be seen that as the amount of glycyrrhizin administered increases, the difference between the curves at the start of the experiment and at the end of the experiment tends to increase, indicating that administration of glycyrrhizin is effective in increasing the weight of young fish. Although the cause of this is unknown, it may be considered to be one of the following. ■ Glycyrrhizin improved feed quality. ■ Improves constitution due to synergistic effect with immune enhancing effect (increase in complement value). ■ Detoxifying effect of glycyrrhizin. ■ Effect of glycyrrhizin on improving liver function. (b) Changes in blood properties: Changes in hematocrit value and serum protein level due to administration of glycyrrhizin are shown in FIG. As shown in the figure, the hematocrit value and the serum protein level both increased with the administration of glycyrrhizin, indicating that the administration improved the properties of the blood. Incidentally, if you feed feed with a high content of oxidized fats and oils, such as minced sardines,
Although it is known that the hematocrit value decreases, administration of glycyrrhizin improves or eliminates this drawback. (Improvement of liver function: Glycyrrhizin administration increases serum G
The effect on the values of OT and GPT is shown in FIG. As shown in the figure, GOT and GPT values decreased by administration of glycyrrhizin and in proportion to the dose.
The fact that glycyrrhizin improves liver function can be seen. -i. Feed for cultivating yellowtail is of poor quality because it contains a large amount of oxidized oil and bacteria, and tends to reduce the liver function of the fish, which often leads to streptococcal infections. This shows the possibility of overcoming this problem through functional enhancement.The food used in this experiment was mainly squid minced sand eel, as mentioned above, but the sardine minced meat that is actually used will probably make a bigger difference. (d) Immune-enhancing effect: Figure 4 shows the effects of glycyrrhizin administration on complement value, lysozyme activity, phagocytosis rate, and agglutination antibody titer, which are indicators related to immunity. In particular, the increase in macrophage phagocytosis rate in the glycyrrhizin-dosing group was remarkable.From these results, glycyrrhizin is effective against fish pathogens, similar to what has already been shown against -11V (AIDS virus, etc.). It is also speculated that it has the effect of strengthening immunity. Therefore, it is expected that the resistance of the treated fish to pathogenic bacteria and viruses will increase, and that it will have the effect of keeping the fish in good health. (e) Infection-preventive effect against streptococcal disease: Figure 5 shows that Streptococcus S-
2433 shares of L Om. From this graph showing the relationship between glycyrrhizin dosage and survival rate when
Although glycyrrhizin does not exhibit a dramatic effect on antibiotics, it is clear that at doses of 50 mg/g or higher, it has a significant effect on increasing the survival rate. Incidentally, in actual fish farms, even if a disease occurs, L
Dm. Since this level is not considered to be basolateral, even this mild effect is sufficient for practical purposes. (51 Dosage and Feed Composition The fish liver function agent and fortification and fish culture feed according to the present invention are administered to target fish in an amount of 5 mg or more, preferably 1011 g or more per IKg of body weight. If desired, sodium salt or potassium salt is used. It may be applied in the form of easily soluble salts such as , or sparingly soluble salts such as calcium salts or aluminum salts.Since the target is fish, it is usually administered by mixing it into the feed. As feed, fish meal, pupa meal, minced raw fish meat, grain flour, wheat gluten, etc. are used depending on the type of fish, but in any case, known binders such as pregelatinized starch, wheat glutin, and casein are used. It is necessary to use sodium, sodium alginate, sodium polyacrylate, sodium carboxymethyl cellulose, various vegetable gums, soybean whey, etc. to give it a viscosity that does not easily disintegrate in water. [Action] Inventor's research It was discovered that glycyrrhizin also has effects on fish such as improving liver function, detoxification, and strengthening immunity.Therefore, if it is used in fish farming,
It is not adversely affected by poor quality feed with a high POV, and exhibits good rearing results, being less susceptible to diseases even in high-density aquaculture. Moreover, glycyrrhizin is a natural product and unlike antibiotics, it does not disrupt the natural microbial balance or accumulate in fish bodies, so it can be suitably used as a safe feed additive. [Examples] Hereinafter, embodiments of the invention will be explained using examples, but the examples are merely for explanation and do not mean any restriction or limitation on the idea of the invention. 1 kg of raw sardines, 50 g of pregelatinized starch, 2 glycyrrhizin
0 mg and vitamin E (antioxidant > 10 mg) were mixed with minced meat, the sown material was extruded into a radon shape, and was lightly dried with hot air to obtain about 1 kg of raw feed for young yellowtail fish. [Effects of the Invention] As explained above and demonstrated. As described above, the present invention provides a means for solving the above problems by developing a non-antibiotic drug for enhancing the biological defense function of fish and a feed containing the drug. (Margins below)
第1図は、グリチルリチンの投与によるブリ稚魚の体重
増加を示すグラフ、第2図は、グリチルリチンの投与に
よるヘマトクリット値及び血清蛋白量の変化を示すグラ
フ、第3図は、グリチルリチンの投与が血清中のGOT
及びGPTの値に及ぼす影響を示すグラフ、第4図は、
グリチルリチンの投与と、補体価、リゾチーム活性、貧
食率及び凝集抗体価の変化との相関を示すグラフ、第5
図は、投与開始から4週間後に、連鎖球菌S−2433
株のLDia量を接種したときのグリチルリチン投与量
と生存率との関係を示すグラフである。各グラフの縦横
パラメータその他の説明は、各図中に記載済み。
購
図
グリチルリチン添加量
(岨/体重1にg・日)
グリチルリチン添加量
(mg/体重IKge日)
グリチルリチン添加量
(脂g/体重IKg・日)
グリチルリチン添加量
(IIg/体重IKg・日)
グリチルリチン添加量
(mg/体重IKg・日)Figure 1 is a graph showing the weight gain of yellowtail fry due to the administration of glycyrrhizin. Figure 2 is a graph showing the change in hematocrit value and serum protein level due to the administration of glycyrrhizin. Figure 3 is a graph showing the increase in body weight of yellowtail fry due to the administration of glycyrrhizin. GOT
A graph showing the influence on the value of GPT and GPT, FIG.
Graph showing the correlation between administration of glycyrrhizin and changes in complement value, lysozyme activity, hypophagia rate, and agglutinating antibody titer, 5th
The figure shows Streptococcus S-2433 after 4 weeks from the start of administration.
It is a graph showing the relationship between glycyrrhizin dosage and survival rate when the LDia amount of the strain is inoculated. The vertical and horizontal parameters of each graph and other explanations are already written in each figure. Added amount of glycyrrhizin (g fat/1 kg body weight/day) Added amount of glycyrrhizin (mg/I kg body weight/day) Added amount of glycyrrhizin (g fat/I kg body weight/day) Added amount of glycyrrhizin (II g/I kg body weight/day) Added glycyrrhizin Amount (mg/body weight IKg/day)
Claims (1)
。 2 グリチルリチンを有効成分として含む養魚用餌料。[Claims] 1. An immune enhancer for fish containing glycyrrhizin as an active ingredient. 2. Fish feed containing glycyrrhizin as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1073152A JP2840851B2 (en) | 1989-03-23 | 1989-03-23 | Fish immunopotentiator and fish culture feed |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1073152A JP2840851B2 (en) | 1989-03-23 | 1989-03-23 | Fish immunopotentiator and fish culture feed |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02250832A true JPH02250832A (en) | 1990-10-08 |
JP2840851B2 JP2840851B2 (en) | 1998-12-24 |
Family
ID=13509925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1073152A Expired - Lifetime JP2840851B2 (en) | 1989-03-23 | 1989-03-23 | Fish immunopotentiator and fish culture feed |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2840851B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008960A1 (en) * | 1995-09-05 | 1997-03-13 | Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh | Antistress agents for aquatic animals |
US7816340B2 (en) | 2001-11-30 | 2010-10-19 | Fmc Biopolymer As | Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid |
CN103070929A (en) * | 2013-02-01 | 2013-05-01 | 中国水产科学研究院黑龙江水产研究所 | Immunopotentiator for oncorhynchus masou masou |
-
1989
- 1989-03-23 JP JP1073152A patent/JP2840851B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008960A1 (en) * | 1995-09-05 | 1997-03-13 | Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh | Antistress agents for aquatic animals |
AU718898B2 (en) * | 1995-09-05 | 2000-04-20 | Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh | Anti-stress agents for aquatic animals |
US6306453B1 (en) | 1995-09-05 | 2001-10-23 | Warner-Lambert Company | Anti-stress agents for aquatic animals |
US7816340B2 (en) | 2001-11-30 | 2010-10-19 | Fmc Biopolymer As | Oral immunostimulation of fish from (1-4) linked β-D-mannuronic acid |
CN103070929A (en) * | 2013-02-01 | 2013-05-01 | 中国水产科学研究院黑龙江水产研究所 | Immunopotentiator for oncorhynchus masou masou |
Also Published As
Publication number | Publication date |
---|---|
JP2840851B2 (en) | 1998-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100101742A (en) | Functional feed additives of marine fisheries and feeds for marine fisheries using thereof | |
Ashida et al. | Immunostimulatory effects of fermented vegetable product on the non-specific immunity of Japanese flounder Paralichthys olivaceus | |
Meyers et al. | First report of viral erythrocytic necrosis in Alaska, USA, associated with epizootic mortality in Pacific herring, Clupea harengus pallasi (Valenciennes) | |
JP4052534B2 (en) | Seafood products and feed | |
KR20030069506A (en) | Anti-white spot syndrome virus igy | |
JPH02250832A (en) | Immunological enhancing agent for fishes and feed for fish-farming | |
CN112891363B (en) | New Zealand vitexin 2 and new Zealand vitexin 3 application | |
JP3534792B2 (en) | Disease resistant feed | |
JP6862541B2 (en) | Aquatic animal feed | |
JP3013871B2 (en) | Method for activating immune activity of marine cultured fish | |
FR2472389A1 (en) | ANTIBIOTIC COMPOSITIONS CONTAINING MACROLIDE AND AMINOHETEROSIDE | |
JP2824185B2 (en) | Fish immunostimulants | |
JPH05176689A (en) | Feed for culturing fish | |
JPH0244814B2 (en) | ||
CN114711347B (en) | Combined preparation for improving disease resistance of marine cultured fish, preparation method and application thereof | |
JP3103615B2 (en) | Preventive and therapeutic agent for pathogen infection added to formulated feed for cultured aquatic animals | |
JP2002199848A (en) | Formulated feed for aquatic invertebrate | |
JPH0748274A (en) | Production of preventing and therapeutic feed for pathogenic microbism in farming fishery | |
CN109385406A (en) | One plant of vibrio parahaemolyticus phage and its application in terms of enhancing aquatic livestock immunity | |
CN110721174B (en) | Medicine for preventing and treating fish myxosporidiosis | |
JPH0967265A (en) | Antiviral agent against pathogenic virus of fishes | |
Nakajima | Epigenetic Activation of Animals, Fish, Crustaceans, Mollusks, and Plants by Administration of Dimethylsulfoniopropionate in Green Sea Algae | |
US6908627B2 (en) | Conditioned media for inhibiting growth of tumor cells | |
JPH06217712A (en) | Feed for crustacean | |
RU2236248C2 (en) | Immunotropic preparation "vitulin" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071023 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091023 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091023 Year of fee payment: 11 |